The Cardiolipin Antibody (ACL) - IgG Test is a crucial diagnostic blood test used to detect and quantify IgG class antibodies directed against cardiolipin, a key phospholipid found in cell membranes. This test is a primary tool in the diagnosis of Antiphospholipid Syndrome (APS), an autoimmune disorder characterized by unexplained blood clotting (thrombosis) and pregnancy-related complications, such as recurrent miscarriages. Elevated levels of IgG-type ACL antibodies are strongly associated with the risk of these thrombotic events. The test is often ordered alongside IgM and IgA isotypes to provide a comprehensive profile for APS assessment and management.

The Cardiac Profile M test is a comprehensive blood package designed to evaluate overall heart health and assess cardiovascular disease risks. Typically consisting of multiple key parameters, this panel combines a complete lipid profile—measuring cholesterol components like HDL, LDL, and triglycerides—with critical cardiac risk markers. By analyzing these specific biochemical indicators, the test helps clinicians identify hidden vulnerabilities, monitor cholesterol management, and detect early signs of potential heart conditions. It serves as a valuable diagnostic tool for preventive health screenings, enabling timely interventions and personalized lifestyle or therapeutic strategies to protect long-term cardiac wellness.

The Cardiac Profile C test is an advanced, comprehensive diagnostic evaluation designed to provide an in-depth analysis of cardiovascular health and intricate heart disease risks. Building upon standard and intermediate screenings, this specialized panel frequently includes high-sensitivity cardiac markers, advanced lipid fractionations, genetic or inflammatory indicators, and specialized coagulation factors. By detecting subtle vascular inflammation, micro-vascular stress, and precise lipoprotein particle sizes, the Cardiac Profile C test offers clinicians granular insight into a patient's long-term wellness. This high-resolution diagnostic tool enables fully personalized preventive strategies, early intervention, and optimized therapeutic management for long-term cardiac protection.

The Carcinoembryonic Antigen (CEA) test is a blood test that measures the levels of CEA, a type of protein typically found in the tissue of developing fetuses. In healthy adults, blood levels of CEA are very low. However, certain types of cancers can cause these levels to rise significantly, most notably colorectal cancer, as well as cancers of the pancreas, breast, lungs, and stomach.
Doctors primarily use the CEA test to monitor how well cancer treatments are working, check for disease recurrence after therapy, or help stage certain malignancies. It serves as an essential biomarker for ongoing cancer management.

The Cancer Detection Panel for Men is a comprehensive diagnostic screening designed to identify potential cancer biomarkers and early-stage malignancies specific to male health.
This multi-test panel typically evaluates key tumor markers such as PSA (Prostate-Specific Antigen) for prostate health, along with blood tests for gastrointestinal, liver, and lung indicators like CEA and AFP. By assessing these biological red flags, the panel helps physicians catch abnormalities before symptoms arise. It is an invaluable preventative tool for proactive health management, enabling early intervention, more effective treatment options, and significantly improved long-term survival outcomes for men.

A 24-hour urine calcium-to-creatinine ratio test measures the amount of calcium released in your urine over a full day, compared against creatinine, a steady muscle waste product. Collecting urine for 24 hours helps doctors account for daily fluctuations in your body's chemistry. This diagnostic tool is commonly used to evaluate mineral balance, assess the underlying causes of recurrent kidney stones, monitor metabolic bone diseases like osteoporosis, and check parathyroid gland function. Abnormal calcium excretion levels can highlight how well your kidneys process minerals, guiding targeted medical treatments and dietary management plans.

The cadmium spot urine test measures the level of the toxic heavy metal cadmium in a random urine sample, offering a snapshot of current bodily burden and renal excretion. Because cadmium accumulates primarily in the renal cortex over a long biological half-life, urinary testing is especially useful for evaluating chronic exposure and assessing potential kidney dysfunction. Clinicians typically order this test to monitor occupational safety compliance among industrial workers, investigate heavy metal toxicity, or track environmental exposure risks. Results are often normalized against urine creatinine to account for hydration variations and guide appropriate medical management.

A cadmium test measures the concentration of the toxic heavy metal cadmium in blood, urine, or hair samples. Cadmium exposure typically occurs through industrial workplaces, tobacco smoke, contaminated food, or batteries, and the metal can accumulate in organs such as the kidneys and liver over time. This diagnostic test is primarily used to assess acute or chronic heavy metal toxicity, monitor occupational safety compliance, and investigate unexplained renal dysfunction or bone mineral loss. Because cadmium has a long biological half-life, clinical evaluation helps guide removal from exposure sources and directs supportive medical management.

The CA-125 test measures the level of cancer antigen 125 in the blood, a protein often found in higher concentrations on the surface of ovarian cancer cells and some other healthy tissues. It is primarily utilized as a tumor marker to monitor the effectiveness of ovarian cancer treatment and to detect potential disease recurrence. While a valuable tool in management, CA-125 is not a definitive diagnostic test for initial screening, as elevated levels can also be caused by benign conditions such as endometriosis, uterine fibroids, and pelvic inflammatory disease, limiting its specificity.

The CA 72-4 test measures the level of cancer antigen 72-4, a tumor-associated glycoprotein found in the blood. It serves primarily as an adjunct biomarker for evaluating and monitoring gastrointestinal malignancies, most notably gastric (stomach) cancer, as well as tracking potential disease recurrence or treatment efficacy. Additionally, CA 72-4 is sometimes utilized alongside other markers, such as CA 125, in the management of ovarian and other epithelial cancers. Because elevated concentrations can also occur in benign inflammatory conditions, the test is not used for standalone screening and requires correlation with clinical findings.

The CA 19-9 test measures the concentration of carbohydrate antigen 19-9, a tumor-associated mucin protein, in the bloodstream. It is primarily utilized as a vital serum biomarker to monitor disease progression, evaluate treatment efficacy, and detect potential recurrence in patients diagnosed with pancreatic cancer. Because levels can also be elevated in other gastrointestinal malignancies, such as cholangiocarcinoma or colorectal cancer, as well as benign conditions like biliary obstruction or pancreatitis, the test is not recommended as a standalone screening tool. Instead, clinicians integrate CA 19-9 results alongside imaging studies and clinical evaluations for comprehensive oncological management.

The C1q Antibodies test, serum measures the levels of autoantibodies directed against the C1q protein, a crucial component of the classical complement pathway. Detecting these antibodies is particularly valuable in the evaluation, diagnosis, and monitoring of systemic lupus erythematosus (SLE), as well as associated complications like lupus nephritis. Elevated titers of anti-C1q antibodies strongly correlate with active renal disease and severe inflammation. Clinicians utilize this specialized immunological assay alongside other complement markers to assess disease activity, predict flare-ups, and guide targeted therapeutic management for autoimmune disorders affecting multiple vital organ systems.